Schwab Charles Investment Management Inc. decreased its holdings in Anika Therapeutics Inc (NASDAQ:ANIK) by 6.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 65,865 shares of the biotechnology company’s stock after selling 4,414 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.45% of Anika Therapeutics worth $3,821,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in ANIK. Wells Fargo & Company MN raised its stake in Anika Therapeutics by 25.0% during the third quarter. Wells Fargo & Company MN now owns 209,928 shares of the biotechnology company’s stock valued at $12,176,000 after buying an additional 42,015 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Anika Therapeutics by 2,781.9% during the third quarter. JPMorgan Chase & Co. now owns 16,859 shares of the biotechnology company’s stock valued at $982,000 after buying an additional 16,274 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Anika Therapeutics during the third quarter valued at approximately $118,000. Advisors Asset Management Inc. acquired a new stake in Anika Therapeutics during the third quarter valued at approximately $333,000. Finally, Kayne Anderson Rudnick Investment Management LLC raised its stake in Anika Therapeutics by 16.4% during the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,656,918 shares of the biotechnology company’s stock valued at $96,101,000 after buying an additional 233,325 shares in the last quarter. Institutional investors and hedge funds own 84.86% of the company’s stock.
ANIK has been the topic of several research reports. Barrington Research upped their price objective on Anika Therapeutics from $53.00 to $57.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. BidaskClub cut Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 14th. First Analysis upgraded Anika Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $45.00 to $68.00 in a research note on Wednesday, January 24th. Finally, Sidoti initiated coverage on Anika Therapeutics in a research note on Friday, January 26th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $62.50.
In other news, insider Richard Hague sold 5,250 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total transaction of $286,020.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.57% of the stock is currently owned by corporate insiders.
Anika Therapeutics Inc (NASDAQ:ANIK) traded down $2.24 during trading hours on Monday, hitting $62.36. The stock had a trading volume of 89,258 shares, compared to its average volume of 72,190. The company has a market capitalization of $947.15, a price-to-earnings ratio of 29.28, a PEG ratio of 3.92 and a beta of 1.60. Anika Therapeutics Inc has a 52 week low of $41.64 and a 52 week high of $69.81.
ILLEGAL ACTIVITY WARNING: “Schwab Charles Investment Management Inc. Sells 4,414 Shares of Anika Therapeutics Inc (ANIK)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/05/anika-therapeutics-inc-anik-shares-sold-by-schwab-charles-investment-management-inc.html.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.